Skip to content

Evaluating the clinical and cost effectiveness of breathing support treatment types in infants under 12 months of age with acute bronchiolitis

Breathing Assistance in CHildren with bronchiolitis (BACHb): a group-sequential two-stratum multicentre open-label randomised clinical trial of respiratory support in infants with acute bronchiolitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN52937119
Enrollment
1508
Registered
2023-09-04
Start date
2023-09-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis Respiratory

Interventions

BACHb is a randomised clinical trial – this means children eligible for the study, depending on whether they have moderate or severe bronchiolitis, will be randomly put into one of two groups: Moderat

Sponsors

Imperial College London
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Hospitalised infant aged 70/min, or grunting, or marked chest recession) and/or recurrent short apnoeas (> 3 per hour, each apnoea lasting < 10 sec) [SEVERE BRONCHIOLITIS stratum], OR 2.2. Lack of response to LFNC oxygen up to 2 L/min, as indicated by persistent hypoxia (SpO2 < 90%, or < 92% if age < 6 weeks or if underlying health problems present) and/or moderate respiratory distress (respiratory rate 55-70/min and moderate chest recession) [MODERATE BRONCHIOLITIS stratum].

Exclusion criteria

Exclusion criteria: 1. Clinical decision that the patient needs immediate intubation and ventilation for life-threatening hypoxia, shock or decreased conscious level. 2. Prolonged apnoeas (>10 seconds needing stimulation). 3. Ongoing active air leak (pneumothorax, pneumomediastinum). 4. Received HSO, HFNC or CPAP for over 2 hours in the previous 24 hours. 5. On home ventilation prior to hospital admission. 6. Tracheostomy in place. 7. Choanal atresia/stenosis, midfacial anomalies or recent craniofacial surgery. 8. Previously recruited to the BACHb trial.

Design outcomes

Primary

MeasureTime frame
Time from randomisation to hospital discharge measured using patient records

Secondary

MeasureTime frame
Measured using patient records to end of hospital stay (unless noted otherwise) 1. Proportion of infants experiencing treatment failure 2. Mortality at hospital discharge, day 30 and day 90 3. Proportion of infants requiring intubation and ventilation 4. Proportion of infants requiring admission to an intensive care unit 5. Proportion of infants requiring sedation 6. Duration of oxygen therapy, defined as the time to being free from supplemental oxygen for >4 hours 7. Time to adequate (75%) oral feeding 8. Time ready for hospital discharge, defined as the time from randomisation to latest of time to being free of supplemental oxygen or adequate oral feeding. 9. Patient comfort, assessed by the caregiver using the FLACC scale. 10. Patient comfort, assessed by the parent/guardian using a visual analogue scale 11. Proportion of infants requiring hospital readmission within 30 days 12. Health status at 30 and 90 days 13. Cost-effectiveness expressed in terms of incremental cost per quality-adjusted life year (QALY) gained

Countries

England, Northern Ireland, Scotland, United Kingdom

Contacts

Public ContactRichard Cleaver
r.cleaver@imperial.ac.uk+44 7999 044627

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026